echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Br J Dermatol: Efficacy and safety of ixekizumab and guselkumab in the treatment of moderate to severe plaque psoriasis

    Br J Dermatol: Efficacy and safety of ixekizumab and guselkumab in the treatment of moderate to severe plaque psoriasis

    • Last Update: 2021-12-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In the IXORA-R head-to-head trial, patients with moderate to severe plaque psoriasis treated with the interleukin (IL)-17A inhibitor ixekizumab and the IL-23p19 inhibitor guselkumab achieved psoriasis area and 100% improvement of the severity index (PASI 100)
    .


    Recently, a randomized trial published in Br J Dermatol compared the skin and nail clearance rates after treatment with ixekizumab and guselkumab, as well as patient-reported results


    IXORA-R recruited adults with moderate to severe plaque psoriasis, defined as static physician global assessment ≥3, PASI ≥12, and affected body surface area ≥10%
    .


    Using test Cochran-Mantel-Haenszel performed statistical comparative study, stratified by collection location


    statistics

     

    The results showed that 90% of the 1,027 randomly assigned patients completed the trial (465 out of 520 ixekizumab and 459 out of 507 guselkumab)
    .


    As early as the 2nd to the 16th week, more patients using ixekizumab reached PASI 100 (P <0.


    Quality of Life

    In summary, the results of this study show that Ixekizumab is not inferior to guselkumab in completely removing skin lesions, and it has an advantage in removing nails at the 24th week
    .


    Ixekizumab can clear the skin of patients with moderate to severe plaque psoriasis faster, and the cumulative benefit is greater than that of guselkumab


     

    Original source:

     

    A Blauvelt, C Leonardi, et al.


    A head-to-head comparison of ixekizumab vs.
    guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.